tradingkey.logo


tradingkey.logo


Arcus Biosciences Inc

RCUS
23.100USD
-0.020-0.09%
終倀 12/26, 16:00ET15分遅れの株䟡
2.47B時䟡総額
損倱額盎近12ヶ月PER


Arcus Biosciences Inc

23.100
-0.020-0.09%

詳现情報 Arcus Biosciences Inc 䌁業名

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

Arcus Biosciences Incの䌁業情報


䌁業コヌドRCUS
䌚瀟名Arcus Biosciences Inc
䞊堎日Mar 15, 2018
最高経営責任者「CEO」Rosen (Terry J)
埓業員数627
蚌刞皮類Ordinary Share
決算期末Mar 15
本瀟所圚地3928 Point Eden Way
郜垂HAYWARD
蚌刞取匕所NASDAQ OMX NASDAQ Basic NYSE
囜United States of America
郵䟿番号94545-3719
電話番号15106946200
りェブサむトhttps://arcusbio.com/
䌁業コヌドRCUS
䞊堎日Mar 15, 2018
最高経営責任者「CEO」Rosen (Terry J)

Arcus Biosciences Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
Dr. Andrew Perlman, M.D., Ph.D.
Dr. Andrew Perlman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard Markus, M.D., Ph.D.
Mr. Richard Markus, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kathryn E. Falberg
Ms. Kathryn E. Falberg
Independent Director
Independent Director
--
--
Ms. Jennifer A. Jarrett
Ms. Jennifer A. Jarrett
Chief Operating Officer
Chief Operating Officer
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%

収益内蚳

通貚: USD曎新時刻: Mon, Oct 6
通貚: USD曎新時刻: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
事業別USD
䌚瀟名
収益
比率
License and development services revenue
152.00M
95.00%
Collaboration revenue
8.00M
5.00%
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
事業別USD
䌚瀟名
収益
比率
License and development services revenue
152.00M
95.00%
Collaboration revenue
8.00M
5.00%

株䞻

曎新時刻: Tue, Nov 18
曎新時刻: Tue, Nov 18
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Gilead Sciences Inc
25.58%
BlackRock Institutional Trust Company, N.A.
8.19%
The Vanguard Group, Inc.
5.39%
Point72 Asset Management, L.P.
3.53%
Woodline Partners LP
3.07%
他の
54.25%
株䞻統蚈
株䞻統蚈
比率
Gilead Sciences Inc
25.58%
BlackRock Institutional Trust Company, N.A.
8.19%
The Vanguard Group, Inc.
5.39%
Point72 Asset Management, L.P.
3.53%
Woodline Partners LP
3.07%
他の
54.25%
皮類
株䞻統蚈
比率
Corporation
25.58%
Investment Advisor
25.42%
Hedge Fund
14.42%
Investment Advisor/Hedge Fund
13.42%
Individual Investor
4.49%
Research Firm
3.09%
Venture Capital
2.37%
Pension Fund
0.59%
Bank and Trust
0.25%
他の
10.37%

機関投資家保有株


曎新時刻: Wed, Oct 1
曎新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q3
427
71.30M
52.26%
-5.17M
2025Q2
441
104.25M
98.12%
+5.20M
2025Q1
461
106.23M
100.41%
+7.59M
2024Q4
458
92.45M
92.67%
-8.14M
2024Q3
459
92.17M
107.84%
+6.16M
2024Q2
456
90.82M
107.03%
+3.48M
2024Q1
456
91.60M
108.07%
-2.14M
2023Q4
455
76.21M
102.30%
-15.07M
2023Q3
450
76.35M
103.06%
-17.88M
2023Q2
441
78.29M
107.10%
-16.66M
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Gilead Sciences Inc
31.42M
29.53%
--
--
Jul 13, 2025
BlackRock Institutional Trust Company, N.A.
10.09M
9.48%
+407.08K
+4.20%
Jun 30, 2025
The Vanguard Group, Inc.
6.54M
6.15%
-131.56K
-1.97%
Jun 30, 2025
Point72 Asset Management, L.P.
5.97M
5.61%
+3.10M
+108.11%
Jun 30, 2025
Woodline Partners LP
4.00M
3.76%
-1.13M
-21.99%
Jun 30, 2025
Suvretta Capital Management, LLC
3.69M
3.47%
+1.13M
+44.05%
Jun 30, 2025
State Street Investment Management (US)
3.63M
3.41%
-65.66K
-1.78%
Jun 30, 2025
Rosen Terry Jay
2.57M
2.42%
-472.90K
-15.53%
Mar 01, 2025
Fidelity Management & Research Company LLC
2.27M
2.13%
-1.86M
-45.07%
Jun 30, 2025
Invus Financial Advisors, LLC
1.61M
1.51%
--
--
Jun 30, 2025
詳现を芋る

関連ETF


曎新時刻: Tue, Dec 2
曎新時刻: Tue, Dec 2
銘柄名
比率
iShares Genomics Immunology and Healthcare ETF
2.68%
Virtus LifeSci Biotech Clinical Trials ETF
1.43%
ALPS Medical Breakthroughs ETF
0.9%
Invesco S&P SmallCap Health Care ETF
0.84%
Tema Oncology ETF
0.75%
Invesco S&P SmallCap 600 Pure Growth ETF
0.69%
iShares Health Innovation Active ETF
0.52%
State Street SPDR S&P Biotech ETF
0.34%
Direxion Daily S&P Biotech Bull 3X Shares
0.21%
State Street SPDR S&P 600 Small Cap Growth ETF
0.19%
詳现を芋る
iShares Genomics Immunology and Healthcare ETF
比率2.68%
Virtus LifeSci Biotech Clinical Trials ETF
比率1.43%
ALPS Medical Breakthroughs ETF
比率0.9%
Invesco S&P SmallCap Health Care ETF
比率0.84%
Tema Oncology ETF
比率0.75%
Invesco S&P SmallCap 600 Pure Growth ETF
比率0.69%
iShares Health Innovation Active ETF
比率0.52%
State Street SPDR S&P Biotech ETF
比率0.34%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.21%
State Street SPDR S&P 600 Small Cap Growth ETF
比率0.19%

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
皮類
比率
デヌタなし
日付
皮類
比率
デヌタなし

よくある質問

Arcus Biosciences Incの䞊䜍5名の株䞻は誰ですか


Arcus Biosciences Incの䞊䜍5名の株䞻は以䞋のずおりです。
Gilead Sciences Incは31.42M株を保有しおおり、これは党䜓の29.53%に盞圓したす。
BlackRock Institutional Trust Company, N.A.は10.09M株を保有しおおり、これは党䜓の9.48%に盞圓したす。
The Vanguard Group, Inc.は6.54M株を保有しおおり、これは党䜓の6.15%に盞圓したす。
Point72 Asset Management, L.P.は5.97M株を保有しおおり、これは党䜓の5.61%に盞圓したす。
Woodline Partners LPは4.00M株を保有しおおり、これは党䜓の3.76%に盞圓したす。

Arcus Biosciences Incの株䞻タむプ䞊䜍3皮は䜕ですか


Arcus Biosciences Incの株䞻タむプ䞊䜍3皮は、
Gilead Sciences Inc
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.

Arcus Biosciences IncRCUSの株匏を保有しおいる機関の数はいく぀ですか


2025Q3時点で、Arcus Biosciences Incの株匏を保有しおいる機関は427瀟あり、保有株匏の総垂堎䟡倀は玄71.30Mで、党䜓の52.26%を占めおいたす。2025Q2ず比范しお、機関の持ち株は-45.86%増加しおいたす。

Arcus Biosciences Incの最倧の収益源は䜕ですか


FY2025Q2においお、License and development services revenue郚門がArcus Biosciences Incにずっお最倧の収益を生み出しおおり、その金額は152.00Mで、党収益の95.00%を占めおいたす。
KeyAI
î™